Invagen Pharmaceuticals Inc

Drug firm Cipla on Tuesday said its US arm InvaGen Pharmaceuticals Inc has received a final approval from the US Food and Drug Administration (FDA) to market generic Bupropion Hydrochloride extended release tablets used for treatment of major depressive disorder.

India's fourth-largest drugmaker by sales will buy privately-held firms InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc, gaining multiple products in the areas of anti-infectives, diabetes and central nervous system disorders.

Drug firm Cipla on Tuesday said its US arm InvaGen Pharmaceuticals Inc has received a final approval from the US Food and Drug Administration (FDA) to market generic Bupropion Hydrochloride extended release tablets used for treatment of major depressive disorder.

India's fourth-largest drugmaker by sales will buy privately-held firms InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc, gaining multiple products in the areas of anti-infectives, diabetes and central nervous system disorders.